featured
Quizartinib vs Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Quizartinib Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukaemia (QuANTUM-R): A Multicentre, Randomised, Controlled, Open-Label, Phase 3 Trial
Lancet Oncol 2019 Jun 04;[EPub Ahead of Print], JE Cortes, S Khaled, G Martinelli, AE Perl, S Ganguly, N Russell, A Krämer, H Dombret, D Hogge, BA Jonas, AY Leung, P Mehta, P Montesinos, M Radsak, S Sica, M Arunachalam, M Holmes, K Kobayashi, R Namuyinga, N Ge, A Yver, Y Zhang, MJ LevisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.